**Table 2: Distribution of Trial Designs by Disease Category and Sex Inclusion Criteria**

| Disease Category | Total Trials | Both Sexes n (%) | Female Only n (%) | Male Only n (%) |
|-----------------|--------------|------------------|-------------------|-----------------|
| COVID-19 | 310 | 309 (99.7) | 1 (0.3) | 0 (0.0) |
| HIV/AIDS | 653 | 559 (85.6) | 33 (5.1) | 61 (9.3) |
| Cancer | 59 | 55 (93.2) | 2 (3.4) | 2 (3.4) |
| Cardiovascular | 13 | 13 (100.0) | 0 (0.0) | 0 (0.0) |
| Infectious Disease | 102 | 99 (97.1) | 3 (2.9) | 0 (0.0) |
| Respiratory | 29 | 29 (100.0) | 0 (0.0) | 0 (0.0) |
| Mental Health | 3 | 3 (100.0) | 0 (0.0) | 0 (0.0) |
| Diabetes | 1 | 1 (100.0) | 0 (0.0) | 0 (0.0) |
| Other | 655 | 623 (95.1) | 22 (3.4) | 9 (1.4) |
| **Total** | **1,825** | **1,691 (92.7)** | **61 (3.3)** | **72 (3.9)** |

Note: Percentages may not sum to 100% due to rounding. This table shows the distribution of trial designs, demonstrating how different approaches to sex inclusion combine to achieve overall statistical equity in representation.
